Artoss Foot and Ankle Surgery Registry

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

May 10, 2024

Study Completion Date

May 10, 2024

Conditions
Arthritis FootTrauma InjuryDeformity; Bone
Interventions
OTHER

NanoBone Bone Graft Substitute

Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.

Trial Locations (8)

34239

Florida Orthopedic Foot & Ankle Center, Sarasota

46254

Podiatry Associates of Indiana, Indianapolis

46901

Hoosier Foot and Ankle, Kokomo

50266

The Iowa Clinic, West Des Moines

55805

Orthopedic Associates of Duluth, Duluth

60435

Illinois Orthopedic Institute, Joliet

61270

Morrison Hospital, Morrison

85251

Phoenix Foot and Ankle Institute, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Artoss Inc.

INDUSTRY

NCT04503759 - Artoss Foot and Ankle Surgery Registry | Biotech Hunter | Biotech Hunter